SOST and type 2 diabetes mellitus: Two out of three Mendelian randomisation studies provided further evidence for increased cardiovascular risk, with those genetically predisposed to lower sclerostin found to be at increased risk of myocardial infarction and T2D [38, 39] and one study finding greater coronary arterial calcification [38].